
Nurturing the entrepreneurial capabilities of academic scientists can enable rapid response to crises
AbCellera Biologics Inc was the first to co-develop an antibody therapeutic for COVID-19, it was the first to receive FDA Emergency Use Authorisation and by 2021 had prevented more than 11,000 deaths in the US alone. This case-study illustrates how the strategy taken by the scientist-entrepreneur before formation of an academic spinout can make a significant impact on its success.










